Ataxin-1 (ATXN1)

Ataxin-1 (ATXN1)

<div class="infobox" style="float:right; background:#f8f9fa; border:1px solid #ddd; padding:10px; margin:0 0 10px 10px; width:280px;">
<h3 style="margin-top:0; border-bottom:1px solid #ddd;">Ataxin-1 / ATXN1</h3>
<ul style="list-style:none; padding:0; margin:5px 0;">
<li><strong>UniProt:</strong> [P54253](https://www.uniprot.org/uniprot/P54253)</li>
<li><strong>Gene:</strong> [ATXN1](/entities/atxn1)</li>
<li><strong>Aliases:</strong> ATX1, SCA1</li>
<li><strong>MW:</strong> ~87 kDa (varies with polyQ length)</li>
<li><strong>Localization:</strong> Nucleus, cytoplasm</li>
<li><strong>PDB:</strong> [4AQP](https://www.rcsb.org/structure/4AQP)</li>
</ul>
</div>

Overview

Ataxin-1 (ATXN1) is a nuclear-cytoplasmic shuttling protein that plays roles in transcriptional regulation, RNA processing, and synaptic development. Expansions of a CAG trinucleotide repeat in the ATXN1 gene cause Spinocerebellar Ataxia Type 1 (SCA1), an autosomal dominant neurodegenerative disorder characterized by progressive cerebellar degeneration and brainstem dysfunction.[@orr1993]

Structure and Domains

Ataxin-1 contains several functional domains:

• AXH domain (Ataxin-1/HBP1) — mediates protein-protein interactions and RNA binding
• Polyglutamine tract — CAG repeat region (normally 6-44 repeats; pathogenic >39)
• Nuclear localization signal (NLS) — required for nuclear import
• Nuclear export signal (NES) — regulates cytoplasmic shuttling
• Serine 776 — critical phosphorylation site regulating stability and toxicity

Ataxin-1 (ATXN1)

<div class="infobox" style="float:right; background:#f8f9fa; border:1px solid #ddd; padding:10px; margin:0 0 10px 10px; width:280px;">
<h3 style="margin-top:0; border-bottom:1px solid #ddd;">Ataxin-1 / ATXN1</h3>
<ul style="list-style:none; padding:0; margin:5px 0;">
<li><strong>UniProt:</strong> [P54253](https://www.uniprot.org/uniprot/P54253)</li>
<li><strong>Gene:</strong> [ATXN1](/entities/atxn1)</li>
<li><strong>Aliases:</strong> ATX1, SCA1</li>
<li><strong>MW:</strong> ~87 kDa (varies with polyQ length)</li>
<li><strong>Localization:</strong> Nucleus, cytoplasm</li>
<li><strong>PDB:</strong> [4AQP](https://www.rcsb.org/structure/4AQP)</li>
</ul>
</div>

Overview

Ataxin-1 (ATXN1) is a nuclear-cytoplasmic shuttling protein that plays roles in transcriptional regulation, RNA processing, and synaptic development. Expansions of a CAG trinucleotide repeat in the ATXN1 gene cause Spinocerebellar Ataxia Type 1 (SCA1), an autosomal dominant neurodegenerative disorder characterized by progressive cerebellar degeneration and brainstem dysfunction.[@orr1993]

Structure and Domains

Ataxin-1 contains several functional domains:

• AXH domain (Ataxin-1/HBP1) — mediates protein-protein interactions and RNA binding
• Polyglutamine tract — CAG repeat region (normally 6-44 repeats; pathogenic >39)
• Nuclear localization signal (NLS) — required for nuclear import
• Nuclear export signal (NES) — regulates cytoplasmic shuttling
• Serine 776 — critical phosphorylation site regulating stability and toxicity

Normal Function

Transcriptional Regulation

Ataxin-1 functions in transcriptional complexes:

RNA Processing and Splicing

The AXH domain binds RNA and influences:[@lam2012]

• Alternative splicing of neuronal transcripts
• RNA stability and localization
• microRNA biogenesis pathways

Synaptic Development

Ataxin-1 is essential for:

• Cerebellar Purkinje cell development
• Dendritic arborization
• Synaptic plasticity and motor learning

Role in Neurodegeneration

Spinocerebellar Ataxia Type 1 (SCA1)

CAG repeat expansion causes SCA1 through multiple mechanisms:[@klement1998]

Gain-of-Function Toxicity

Loss-of-Normal-Function

Pathological Features

• Nuclear inclusions — Contain expanded ataxin-1, ubiquitin, and chaperones
• Purkinje cell loss — Selective vulnerability of cerebellar Purkinje [neurons](/entities/neurons)
• Brainstem degeneration — Affects pontine nuclei and inferior olive

Modifier Genes

SCA1 severity is modified by:

• PNKP — DNA repair enzyme; mutations worsen ataxia
• RORA — Transcription factor; affects Purkinje cell survival
• PSMC3 — Proteasome component; influences protein clearance[@park2021]

Therapeutic Targeting

Antisense Oligonucleotides (ASOs)

• ATXN1-targeting ASOs — Reduce ataxin-1 expression in preclinical models
• Clinical development — Potential for allele-selective approaches

Small Molecule Approaches

| Strategy | Mechanism | Status |
|----------|-----------|--------|
| S776 phosphorylation inhibitors | Reduce mutant ataxin-1 stability | Preclinical |
| AXH domain disruptors | Prevent protein-protein interactions | Discovery |
| Proteostasis modulators | Enhance clearance of mutant protein | Preclinical |

Gene Therapy

• AAV-mediated RNA interference — Knockdown of mutant ATXN1
• CRISPR-based allele editing — Targeting expanded CAG repeats

Protein Interactions

| Partner | Function | Disease Relevance |
|---------|----------|-------------------|
| CIC (Capicua) | Transcriptional repressor | SCA1 transcriptional dysregulation |
| RBM17 | RNA splicing factor | Altered splicing in SCA1 |
| ATXN1L | Ataxin-1-like protein | Functional redundancy |
| 14-3-3 proteins | Phospho-binding proteins | S776-mediated stabilization |

Pathway & Interaction Diagram

Interactive diagram showing ATXN1's key relationships in the SciDEX knowledge graph (8 connections shown).

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [UniProt: P54253](https://www.uniprot.org/uniprot/P54253)
• [PDB structures](https://www.rcsb.org/search?q=uniprot:P54253)

References